IDEC is a leader in the discovery, development, and commercialization
of targeted immunotherapies for the treatment of cancer and autoimmune
diseases. IDEC discovered and developed the first commercially
available radioimmunotherapy product (Zevalin®) approved in the United
States, which is used to treat certain non-Hodgkin's lymphomas. IDEC
also discovered and, with co-promotion partner Genentech, Inc.,
developed the first monoclonal antibody pr...
more
IDEC is a leader in the discovery, development, and commercialization
of targeted immunotherapies for the treatment of cancer and autoimmune
diseases. IDEC discovered and developed the first commercially
available radioimmunotherapy product (Zevalin®) approved in the United
States, which is used to treat certain non-Hodgkin's lymphomas. IDEC
also discovered and, with co-promotion partner Genentech, Inc.,
developed the first monoclonal antibody product (Rituxan®) approved in
the United States for the treatment of cancer. Rituxan is approved in
over 70 countries worldwide and is also used to treat various types of
non-Hodgkin's lymphomas. IDEC is a San Diego-based, integrated
biopharmaceutical company with multiple products in clinical stage
development and strategic alliances in a variety of research platforms.
less
